"Ah? Human Hibernation?
How much would it cost to develop that technology?"
After Lin Jia returned to Shanghai from Zhejiang Province, Chen Yuanguang roughly explained what businesses the tech company he planned to establish would engage in when discussing his future plans with her.
Chen Yuanguang's answer was far removed from what Lin Jia had expected.
Lin Jia had made many guesses about the business Chen Yuanguang's tech company would undertake.
The first was vaccine-related services—providing services to vaccine companies, such as mutation-site prediction, virus prediction, and so on. There was plenty that could be done. Chen Yuanguang had already made a name for himself, and as long as he revealed his intentions, countless pharmaceutical companies both at home and abroad would be willing to cooperate. It was the easy route.
The second was pharmaceutical research outsourcing, similar to WuXi AppTec's model. They could leverage Chen Yuanguang's scientific research capabilities to assemble a team, use his overseas reputation to take on contracts, gradually grow the business, and conduct some new drug research at the same time.
The third was an AI pharmaceutical R&D platform, specializing in providing services for new drug development. Simply put, they would make AI tools to empower new drug R&D.
These three lines of business could advance in parallel. The first and second would ensure cash flow, while the third would require early investment. Once they grew larger, it could absolutely become a monopoly business within a niche industry.
With Chen Yuanguang's reputation and her domestic connections, once they reached a certain scale, they could list on the STAR Market. After going public, they would have a steady stream of cash flow to cultivate the AI pharmaceutical R&D platform. Lin Jia had been very confident they could build it into something big and strong.
This was